FLINT, Mich. — July 31, 2017 — The nation’s largest independent specialty pharmacy has been ranked among Crain’s Fast 50 for the second consecutive year.

Diplomat Pharmacy, Inc. (NYSE: DPLO), has been named one of the fastest-growing companies in southeast Michigan by Crain’s Detroit Business.

The annual Crain’s Fast 50 feature ranks private and public companies by three-year revenue growth. This year’s edition measures growth from 2013 to 2016.

To view the complete list, visit crainsdetroit.com/awards/fast_50/2017.

“Being named among Crain’s Fast 50 is an incredible triumph,” said Phil Hagerman, CEO and chairman of Diplomat. “We’ve made several great strides over the past few years. We grew in revenue from existing drugs, continued to win access to meaningful specialty drug approvals, and strengthened our expertise and national footprint across complex disease states through key acquisitions.”

Diplomat President Paul Urick added, “Our growth is driven by all aspects of our business. We are excited to continue to grow and remain dedicated to Michigan and our hometown of Flint.”

To learn more about Diplomat, visit diplomat.is.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is. 

### 

CONTACT:
Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Twitter